Pasadena Private Wealth’s Harvard Bioscience HBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $108K | Buy |
243,911
+45,872
| +23% | +$20.4K | 0.02% | 186 |
|
|
2025
Q1 | $112K | Hold |
198,039
| – | – | 0.02% | 178 |
|
|
2024
Q4 | $418K | Hold |
198,039
| – | – | 0.09% | 100 |
|
|
2024
Q3 | $533K | Hold |
198,039
| – | – | 0.11% | 82 |
|
|
2024
Q2 | $564K | Buy |
198,039
+25,554
| +15% | +$72.8K | 0.13% | 74 |
|
|
2024
Q1 | $731K | Hold |
172,485
| – | – | 0.17% | 63 |
|
|
2023
Q4 | $923K | Hold |
172,485
| – | – | 0.23% | 50 |
|
|
2023
Q3 | $742K | Hold |
172,485
| – | – | 0.22% | 38 |
|
|
2023
Q2 | $947K | Buy |
172,485
+38,259
| +29% | +$210K | 0.27% | 35 |
|
|
2023
Q1 | $564K | Hold |
134,226
| – | – | 0.16% | 48 |
|
|
2022
Q4 | $372K | Hold |
134,226
| – | – | 0.11% | 59 |
|
|
2022
Q3 | $344K | Hold |
134,226
| – | – | 0.12% | 59 |
|
|
2022
Q2 | $483K | Buy |
134,226
+16,925
| +14% | +$60.9K | 0.17% | 45 |
|
|
2022
Q1 | $728K | Buy |
117,301
+1,401
| +1% | +$8.7K | 0.24% | 38 |
|
|
2021
Q4 | $817K | Buy |
115,900
+8,150
| +8% | +$57.5K | 0.27% | 40 |
|
|
2021
Q3 | $752K | Buy |
107,750
+4,075
| +4% | +$28.4K | 0.26% | 34 |
|
|
2021
Q2 | $864K | Buy |
103,675
+32,175
| +45% | +$268K | 0.3% | 35 |
|
|
2021
Q1 | $390K | Buy |
71,500
+5,925
| +9% | +$32.3K | 0.14% | 52 |
|
|
2020
Q4 | $281K | Buy |
65,575
+5,925
| +10% | +$25.4K | 0.11% | 58 |
|
|
2020
Q3 | $180K | Buy |
59,650
+3,925
| +7% | +$11.8K | 0.07% | 68 |
|
|
2020
Q2 | $173K | Buy |
55,725
+20,000
| +56% | +$62.1K | 0.07% | 63 |
|
|
2020
Q1 | $83K | Buy |
35,725
+10,325
| +41% | +$24K | 0.03% | 66 |
|
|
2019
Q4 | $77K | Hold |
25,400
| – | – | 0.03% | 61 |
|
|
2019
Q3 | $78K | Buy |
+25,400
| New | +$78K | 0.04% | 56 |
|